Abstract:Virus-like particles (VLPs) constitute a promising alternative as influenza vaccine. They are non-replicative particles that mimic the morphology of native viruses which make them more immunogenic than classical subunit vaccines. In this study, we propose HEK-293 cells in suspension culture in serum-free medium as an efficient platform to produce large quantities of VLPs. For this purpose, a stable cell line expressing the main influenza viral antigens hemagglutinin (HA) and neuraminidase (NA) (subtype H1N1) under the regulation of a cumate inducible promoter was developed (293HA-NA cells). The production of VLPs was evaluated by transient transfection of plasmids encoding human immunodeficiency virus (HIV) Gag or M1 influenza matrix protein. To facilitate the monitoring of VLPs production, Gag was fused to the green fluorescence protein (GFP). The transient transfection of the gag containing plasmid in 293HA-NA cells increased the release of HA and NA seven times more than its counterpart transfected with the M1 encoding plasmid. Consequently, the production of HA-NA containing VLPs using Gag as scaffold was evaluated in a 3-L controlled stirred tank bioreactor. The VLPs secreted in the culture medium were recovered by ultracentrifugation on a sucrose cushion and ultrafiltered by tangential flow filtration. Transmission electron micrographs of final sample revealed the presence of particles with the average typical size (150-200nm) and morphology of HIV-1 immature particles. The concentration of the influenza glycoproteins on the Gag-VLPs was estimated by single radial immunodiffusion and hemagglutination assay for HA and by Dot-Blot for HA and NA. More significantly, intranasal immunization of mice with influenza Gag-VLPs induced strong antigen-specific mucosal and systemic antibody responses and provided full protection against a lethal intranasal challenge with the homologous virus strain. These data suggest that, with further optimization and characterization the process could support mass production of safer and better-controlled VLPs-based influenza vaccine candidate.

Preliminary Study on H1N1 Virus-Like Particle Vaccine

Virus-Like Particle Vaccine Containing Hemagglutinin Confers Protection Against 2009 H1N1 Pandemic Influenza

Virus-like Particle Vaccine Comprised of the HA, NA, and M1 Proteins of an Avian Isolated H5N1 Influenza Virus Induces Protective Immunity Against Homologous and Heterologous Strains in Mice.

Virus-Like Particle Vaccine Induces Protective Immunity Against Homologous and Heterologous Strains of Influenza Virus

A Pandemic H1N1 Influenza Virus-Like Particle Vaccine Induces Cross-Protection in Mice

Induction of Long-Term Protective Immune Responses by Influenza H5N1 Virus-Like Particles

Intramuscular and Intranasal Immunization with an H7N9 Influenza Virus-Like Particle Vaccine Protects Mice Against Lethal Influenza Virus Challenge.

Incorporation of Conserved Nucleoprotein into Influenza Virus-Like Particles Could Provoke a Broad Protective Immune Response in BALB/c Mice and Chickens

Baculovirus-derived influenza virus-like particle confers complete protection against lethal H7N9 avian influenza virus challenge in chickens and mice

H5N1 Influenza Virus-Like Particle Vaccine Protects Mice from Heterologous Virus Challenge Better Than Whole Inactivated Virus.

Preclinical Evaluation of the Safety and Pathogenicity of a Live Attenuated Recombinant Influenza A/H7N9 Seed Strain and Corresponding MF59-adjuvanted Split Vaccine

Immunization with a Low Dose of Hemagglutinin-Encoding Plasmid Protects Against 2009 H1N1 Pandemic Influenza Virus in Mice.

Immune Correlates of Protection Induced by Virus-Like Particles Containing 2009 H1N1 Pandemic Influenza HA, NA or M1 Proteins

Protection Induced by Early Stage Vaccination with Pandemic Influenza Virus-Like Particles.

Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate

Protection Against Influenza H7n9 Virus Challenge with A Recombinant Np-M1-Hsp60 Protein Vaccine Construct in Balb/C Mice

Protection efficacy of the H1 and H3 bivalent virus-like particle vaccine against swine influenza virus infection

Immunogenicity and Protective Efficacy of a Live Attenuated Vaccine Against the 2009 Pandemic A H1N1 in Mice and Ferrets.

Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from That Induced by Split Influenza Virus

Progress in Developing Virus-Like Particle Influenza Vaccines

Insect Cell-Based Quadrivalent Seasonal Influenza Virus-like Particles Vaccine Elicits Potent Immune Responses in Mice